RxDoctor Payments DataLook up a doctor →

Przemyslaw Twardowski, MD

Medical Oncology · Santa Monica, CANPI 1942317987

Payments from drug & device makers

$6,954,195in general payments, 2019–2025

Across 2,032 payments — averaging $3422.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2.1M
  • Merck$1.1M
  • Blue Earth Diagnostics$1.1M
  • Bayer$542K
  • AstraZeneca$303K
  • Janssen Research & Development, LLC$253K
  • plus $1.6M from 47 others
$506in research payments, 2019–2025

Across 3 payments — averaging $168.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$506

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis37$2,079,116
Merck444$1,133,279
Blue Earth Diagnostics50$1,055,034
Bayer423$541,699
AstraZeneca89$303,212
Janssen Research & Development, LLC44$253,117
Astrazeneca UK Limited6$253,106
Pfizer149$174,253
Astellas Pharma US Inc157$165,363
Exelixis Inc.58$161,208
Regeneron32$159,084
Seagen Inc.80$110,497
Dendreon Pharmaceuticals LLC39$107,598
Clovis Oncology, Inc.24$96,563
Johnson & Johnson132$94,961
Sanofi43$60,876
Astellas Pharma Global Development7$47,495
E.r. Squibb & Sons, L.L.C.39$28,866
AVEO Pharmaceuticals, Inc.29$28,213
Sumitomo Pharma America, Inc.19$23,313
Biontech SE5$18,450
EMD Serono, Inc.9$14,856
Gilead27$13,086
Myovant Sciences Inc.10$10,900
Incyte Corporation6$10,075
Tolmar, Inc.4$2,443
Bristol Myers Squibb1$2,260
Janssen Scientific Affairs, LLC5$1,159
Tolmar Pharmaceuticals, Inc.2$999
Organon1$468
Progenics Pharmaceuticals, Inc.9$441
Biotissue Holdings Inc.6$401
Urogen Pharma, Inc.3$218
Eisai Inc.10$198
Genentech USA, Inc.2$185
Telix Pharmaceuticals1$167
Myriad Genetic Laboratories, Inc.3$157
Roche Diagnostics Corporation1$125
Osiris Therapeutics Inc.2$124
Amgen5$103
Lilly USA, LLC3$98
Regeneron Healthcare Solutions, Inc.2$55
Caris MPI, Inc.2$51
Array Biopharma Inc2$47
Ferring Pharmaceuticals Inc.1$44
Tersera Therapeutics LLC1$39
Smith+Nephew2$33
Tempus AI, Inc1$32
180 Medical, Inc.1$30
AbbVie1$29
Daiichi Sankyo Inc.1$25
Menarini Silicon Biosystems, Inc.1$22
Intuitive Surgical1$22

How this compares

$6,954,195 in reported general payments places this provider in the 95th percentile of 379 medical oncology providers in California.

See all medical oncology providers in California →

Medicare billing

Part B allowed, 2024
$166,212
Medicare patients
299
Services billed
1,564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Santa Monica

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →